Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 11/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13712514 | 0.83 | EPHX1 (0.51) | HSD11B1CYP2C9EPHX1USP30ALDH1A1 | |
| SCHEMBL29042869 | 0.82 | EPHX1 (0.56) | HSD11B1CYP2C9EPHX1USP30ALDH1A1 | |
| SCHEMBL671312 | 0.82 | EPHX1 (0.56) | HSD11B1CYP2C9EPHX1USP30ALDH1A1 | |
| SCHEMBL15170353 | 0.82 | EPHX1 (0.56) | HSD11B1CYP2C9EPHX1USP30ALDH1A1 | |
| SCHEMBL4511809 | 0.80 | OPRK1 (0.41) | HSD11B1CYP2C9EPHX1OPRK1ALDH1A1 | |
| SCHEMBL13696786 | 0.80 | EPHX1 (0.61) | HSD11B1CYP2C9EPHX1USP30ALDH1A1 | |
| SCHEMBL10074964 | 0.80 | EPHX1 (0.65) | HSD11B1CYP2C9EPHX1USP30ALDH1A1 | |
| SCHEMBL672100 | 0.80 | EPHX1 (0.65) | HSD11B1CYP2C9EPHX1USP30ALDH1A1 | |
| SCHEMBL29042880 | 0.80 | EPHX1 (0.61) | HSD11B1CYP2C9EPHX1USP30ALDH1A1 | |
| SCHEMBL13696784 | 0.80 | EPHX1 (0.65) | HSD11B1CYP2C9EPHX1USP30ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239929-A1 | N-Pyrrolidin-3-YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090239929-A1 | N-Pyrrolidin-3-YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239929-A1 | N-Pyrrolidin-3-YL-Amide Derivatives As Serotonin and Noradrenalin Re-Uptake Inhibitors | TPH1, TPH2, HTR1A | HSD11B1 204/4885CYP2C9 129/4885EPHX1 856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.